Rapid community "Healthy Heart" screening to identify people at high risk of cardiovascular events
- 1PocDoc, Vital Signs Solutions Ltd, Cambridge, United Kingdom
- 2Health Innovation North East and North Cumbria, Newcastle upon Tyne, United Kingdom
- 3Howbeck Healthcare, Cheshire, United Kingdom
Abstract
Objectives: To evaluate the proof-of-concept feasibility of identifying individuals at high risk of cardiovascular disease through community-based PocDoc Healthy Heart point-of-care screening in a large, ethnically diverse, disadvantaged real-world cohort in the United Kingdom. Methods: Proof-of-concept, non-randomised, non-interventional real-world cardiovascular disease risk case finding study in adults aged 18 years or older in real-world communities across the United Kingdom. Main outcome measures were identification of individuals with high risk of cardiovascular disease, defined as QRISK3 score ≥10%; and individuals meeting the criteria for weight loss, smoking cessation, or hypertension management services. Results: A total of 4,256 individuals (mean age 49 years, 57% male, 31% body mass index ≥30 kg/m2) were included in the Primary Cohort. The Targeted Outreach and Workplace sub-cohorts comprised 1,970 and 756 individuals, respectively. In the Primary Cohort, 35% (1,486/4,256) had high (>5.0 mmol/L) total serum cholesterol, 10% were smokers, 10% met criteria for weight loss services and 19% met criteria for hypertension management services. QRISK3 scores were generated for individuals who had not previously had a cardiovascular disease event (~90% of screened individuals). A QRISK3 score ≥10% was found in 20% (784/3,842) of individuals in the Primary Cohort, 26% (457/1,743) in the Targeted Outreach sub-cohort, and 6% (41/701) in the Workplace sub-cohort. In the Primary Cohort, 60% (472/784) of individuals with a QRISK3 score ≥10% were not being treated with a lipid-lowering therapy at the time of testing. Conclusions: In this proof-of-concept study, community-based point-of-care screening identified individuals with elevated cardiovascular risk and unmet cardiovascular risk management needs. These findings are hypothesis-generating and provide the rationale for further controlled studies with systematic follow-up and health-economic analyses to evaluate whether this approach can deliver improved clinical and system-level outcomes. Trial registration: ClinicalTrials.gov NCT06258005
Related
- Bringing Cardiovascular Prevention into the Community: Protocol for an Observational Study of a Mosque-Based Health Initiative Combining Education and Cardiovascular Screening
- Refining E-detectioN Tools for Emerging mental disoRders (ENTER) to identify young people at clinical high risk for psychosis in the community: model development and internal validation
- Results of a Community-Based Coronary CT Angiography Screening in Asymptomatic Adults With Cardiovascular Risk Factors: The Broward County Heart Project
- High-throughput screening to identify inhibitors of the MTB CARD•RNA polymerase protein-protein interaction
- Prevalence of NASH/NAFLD in people with obesity who are currently classified as metabolically healthy
BibTeX
@article{roest2026rapid,
title = {{Rapid community "Healthy Heart" screening to identify people at high risk of cardiovascular events}},
author = {Kiran Roest and Catherine Kelly and Tracy Marshall and Emily Whales and Lisa Taylor and Rachel Hatfield and Kate Bunyan and Luke Dawson and Steve Roest and Julia Newton},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0358999},
url = {https://doi.org/10.1371/journal.pone.0358999},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rapid community "Healthy Heart" screening to identify people at high risk of cardiovascular events
AU - Kiran Roest
AU - Catherine Kelly
AU - Tracy Marshall
AU - Emily Whales
AU - Lisa Taylor
AU - Rachel Hatfield
AU - Kate Bunyan
AU - Luke Dawson
AU - Steve Roest
AU - Julia Newton
PY - 2026
DA - 2026/09/29
JO - PLOS One
DO - 10.1371/journal.pone.0358999
UR - https://doi.org/10.1371/journal.pone.0358999
AB - Objectives: To evaluate the proof-of-concept feasibility of identifying individuals at high risk of cardiovascular disease through community-based PocDoc Healthy Heart point-of-care screening in a large, ethnically diverse, disadvantaged real-world cohort in the United Kingdom. Methods: Proof-of-concept, non-randomised, non-interventional real-world cardiovascular disease risk case finding study in adults aged 18 years or older in real-world communities across the United Kingdom. Main outcome measures were identification of individuals with high risk of cardiovascular disease, defined as QRISK3 score ≥10%; and individuals meeting the criteria for weight loss, smoking cessation, or hypertension management services. Results: A total of 4,256 individuals (mean age 49 years, 57% male, 31% body mass index ≥30 kg/m2) were included in the Primary Cohort. The Targeted Outreach and Workplace sub-cohorts comprised 1,970 and 756 individuals, respectively. In the Primary Cohort, 35% (1,486/4,256) had high (>5.0 mmol/L) total serum cholesterol, 10% were smokers, 10% met criteria for weight loss services and 19% met criteria for hypertension management services. QRISK3 scores were generated for individuals who had not previously had a cardiovascular disease event (~90% of screened individuals). A QRISK3 score ≥10% was found in 20% (784/3,842) of individuals in the Primary Cohort, 26% (457/1,743) in the Targeted Outreach sub-cohort, and 6% (41/701) in the Workplace sub-cohort. In the Primary Cohort, 60% (472/784) of individuals with a QRISK3 score ≥10% were not being treated with a lipid-lowering therapy at the time of testing. Conclusions: In this proof-of-concept study, community-based point-of-care screening identified individuals with elevated cardiovascular risk and unmet cardiovascular risk management needs. These findings are hypothesis-generating and provide the rationale for further controlled studies with systematic follow-up and health-economic analyses to evaluate whether this approach can deliver improved clinical and system-level outcomes. Trial registration: ClinicalTrials.gov NCT06258005
SN - 1932-6203
ER -